Table 2.

Details of all thrombotic outcomes

Sex/age	Thrombotic outcome	DOAC dose	Weight (kg)	BMI	Creatinine (mg/dL)	Creatinine clearance (mL/min)	C-trough level (ng/mL)	C-peak level (ng/mL)	CHA2DS2VASc score	Previous stroke/TIA	Inappropriate DOAC prescription	Use of antiplatelet drugs	Use of interfering drugs
M/78	Stroke	Apixaban 5 mg BID	90	24.9	1.31	69	94	182	4	Yes	No	No	No
F/78	Stroke	Apixaban 2.5 mg BID	41	18.2	1.31	23	73	84	7	Yes	Yes	No	No
M/71	SVT	Apixaban 5 mg BID	84	25.6	1.20	67	110	150	4	No	No	Yes	No
F/83	Fatal AMI	Apixaban 2.5 mg BID	46	18.7	0.69	44	33	219	4	No	No	No	Yes
M/86	AMI	Apixaban 5 mg BID	86	29.7	1.08	58	106	238	4	No	No	No	No
M/82	AMI	Apixaban 5 mg BID	78	26.4	1.00	63	169	368	4	No	No	Yes	No
M/83	AMI	Apixaban 2.5 mg BID	112	34.6	1.74	50	97	NA	5	No	No	No	No
M/78	Fatal AMI	Apixaban 5 mg BID	66	23.4	1.24	45	32	80	6	No	No	Yes	No
M/62	Stroke	Dabigatran 150 mg BID	85	28.7	0.85	108	68	248	2	No	No	No	No
M/81	DVT	Dabigatran 110 mg BID	73	28.5	1.27	47	90	165	5	Yes	No	No	No
M/67	AMI	Dabigatran 110 mg BID	83	28.1	1.30	65	37	60	3	No	No	Yes	No
M/66	AMI	Dabigatran 150 mg BID	102	32.9	1.37	75	34	NA	4	No	No	Yes	No
M/89	AMI	Dabigatran 110 mg BID	67	21.9	0.91	51	128	NA	3	No	No	No	No
F/83	Stroke	Edoxaban 30 mg	54	23.1	0.75	48	23	101	5	Yes	No	No	No
F/79	Stroke	Edoxaban 30 mg	67	26.2	0.87	55	35	102	5	No	Yes	No	No
M/79	AMI	Edoxaban 30 mg	60	18.5	1.44	35	20	247	5	No	No	Yes	No
M/70	Fatal AMI	Edoxaban 60 mg	64	26.6	1.10	57	40	296	4	No	No	Yes	No
F/72	Fatal AMI	Edoxaban 60 mg	72	28.8	1.00	57	52	NA	3	No	No	No	No
F/79	Fatal stroke	Rivaroxaban 15 mg	55	22.9	0.60	63	17	121	5	No	Yes	No	No
F/89	TIA	Rivaroxaban 15 mg	75	29.3	1.15	39	13	9	5	No	No	Yes	No
M/81	Fatal AMI	Rivaroxaban 20 mg	104	34.0	0.57	150	43	189	6	No	No	Yes	No

AMI, acute myocardial infarction; BID, twice a day (bis in die); DVT, deep vein thrombosis; NA, not available; SVT, superficial vein thrombosis; TIA, transient ischemic attack.